ethyl 1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylate | 952710-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylate
• 英文别名: 1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester；Ethyl 1-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxylate；ethyl 1-[4-(trifluoromethyl)phenyl]pyrazole-4-carboxylate
• CAS: 952710-17-7
• 化学式: C₁₃H₁₁F₃N₂O₂
• 分子量: 284.238
• InChiKey: CVEHAUMJIXVIRF-UHFFFAOYSA-N

物化性质

• 沸点：
  333.5±42.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 以86%的产率得到{1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methanol
  参考文献：
  名称：

  Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains

  摘要：

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.

  DOI：

  10.1021/jm901378u
• 作为产物：
  描述：

  ethyl 5-amino-1-(4-(trifluoromethyl)phenyl)-1H-pyrazole-4-carboxylate 在 亚硝酸异戊酯 作用下， 以 四氢呋喃 为溶剂， 反应 20.0h， 以84%的产率得到ethyl 1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylate
  参考文献：
  名称：

  Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains

  摘要：

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.

  DOI：

  10.1021/jm901378u

文献信息

• BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
  申请人：Kuo Gee-Hong

  公开号：US20070244094A1

  公开（公告）日：2007-10-18

  The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.

  该发明涉及一种化合物，其化学式为（I），可用作PPAR激动剂。还描述了使用该发明的化合物治疗糖尿病、肾病、神经病、视网膜病变、多囊卵巢综合征、高血压、缺血、中风、肠易激综合征、炎症、白内障、心血管疾病、代谢X综合征、高LDL胆固醇血症、血脂异常（包括高甘油三酯血症、高胆固醇血症、混合性高脂血症和低HDL胆固醇血症）、动脉粥样硬化、肥胖以及其他与脂质代谢和能量稳态并发症相关的疾病的药物组合物和治疗方法。
• AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA
  申请人：Luehr Gary W.

  公开号：US20100184815A1

  公开（公告）日：2010-07-22

  Disclosed are compounds of the formula: And pharmaceutically acceptable salts thereof, wherein the variables are as defined herein, which are useful in activating PPARα and in treating atherosclerosis hypercholesterolemia, primary hypercholesterolemia or mixed dyslipidemia, hypertriglyceridemia, Frederickson Types IV and V hyperlipidemia. Pharmaceutical compositions, intermediates useful in the preparation of the compounds of formula I and methods of making the compounds of formula I are also disclosed.

  本发明涉及以下式的化合物及其药学上可接受的盐，其中变量如本文所定义，其在激活PPARα和治疗动脉硬化高胆固醇血症、原发性高胆固醇血症或混合性脂质代谢异常、高三酰甘油血症、Frederickson IV和V型高脂血症方面有用。还公开了制备I式化合物的中间体、制备I式化合物的方法以及药物组合物。
• US7678786B2
  申请人：——

  公开号：US7678786B2

  公开（公告）日：2010-03-16
• US8633184B2
  申请人：——

  公开号：US8633184B2

  公开（公告）日：2014-01-21
• Synthesis and Structure−activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains
  作者：Hamish S. Sutherland、Adrian Blaser、Iveta Kmentova、Scott G. Franzblau、Baojie Wan、Yuehong Wang、Zhenkun Ma、Brian D. Palmer、William A. Denny、Andrew M. Thompson

  DOI：10.1021/jm901378u

  日期：2010.1.28

  Recently described biphenyl analogues Of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.